Jakafi

Feb 06, 2025

JAKAFI’s demand continues to grow in Polycythemia Vera The therapeutic paradigm for Polycythemia Vera patients has shifted significantly in the last few years. Previously, the Polycythemia Vera treatment landscape was dominated by generic medicines such as aspirin, hydroxyurea, interferons, and phlebotomy unti...

Jun 10, 2024

Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis pati...

Oct 17, 2016

Janus Kinase (JAK) inhibitors are the ones that inhibit the functional activity of enzymes that belong to Janus Kinase family such as JAK1, JAK2, JAK3 and TYK2 by interfering in the JAK-STAT signaling pathway. JAK Inhibitors are used for the treatment purpose in cancer and inflammatory diseases like rheuma...